Tasurgratinib for Patients With FGFR2 Gene Fusion–Positive CCA: A Phase 2 Study

March 2024, Vol 5, No 1
The articles in this issue are based on presentations from the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium held January 18-20, 2024, in San Francisco, CA.

Intrahepatic cholangiocarcinoma (iCCA) is a biliary tract cancer that represents an estimated 5% to 30% of primary liver cancers. Patients with CCA are often diagnosed at late stages of the disease and, therefore, generally have a poor prognosis.1,2

There are few treatment options available for patients with surgically unresectable CCA, but the suggested first-line treatment is the combination of gemcitabine plus cisplatin with durvalumab.

Genetic alterations in the fibroblast growth factor receptor 2 (FGFR2) gene can occur in patients with CCA, and FGFR inhibitors are recommended in patients with CCA and FGFR fusions.3,4

Tasurgratinib (E7090) is an oral selective inhibitor of FGFR1, FGFR2, and FGFR3, with the recommended dose being 140 mg daily, as described in the dose-escalation part of a first-in-human phase 1 study.5,6

In a single-arm phase 2 study (NCT04238715) reported at ASCO GI by Junji Furuse, MD, PhD, tasurgratinib was evaluated in patients with FGFR2 fusion–positive CCA after gene fusion status had been confirmed by fluorescence in situ hybridization.

Oral tasurgratinib (140 mg) was administered daily in 28-day cycles to Japanese and Chinese patients with surgically unresectable, advanced, or metastatic CCA until disease progression, drug intolerance, or death.

Patients were included if they had ≥1 prior chemotherapies, including a gemcitabine-based combination, no prior FGFR inhibitor, and an Eastern Cooperative Oncology Group performance status of 0 or 1.

Tumor responses were measured every 8 weeks, and complete and partial responses required radiologic confirmation that occurred at least 28 days later. The primary endpoint was the overall response rate (ORR), and secondary endpoints included disease control rate, clinical benefit rate, duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and safety.

There were 63 patients enrolled in this study (28 Japanese, 35 Chinese) with a median age of 55 years. Of these patients, 23 received 1 prior line of therapy, while all others received ≥2 prior lines of therapy. By March 15, 2023 (data cutoff), 55 patients had discontinued treatment: disease progression, 48; adverse events, 4; patient choice, 2; loss of clinical benefit, 1.

There were 19 (30.2%) patients with a partial response and 31 (49.2%) patients with stable disease. The ORR was 30.2% (2-sided 90% confidence interval [CI], 20.7-41.0; 95% CI, 19.2-43.0) and met the prespecified success criteria. The median TTR and DOR were 1.87 months and 5.6 months, respectively.

Tasurgratinib demonstrated encouraging efficacy in individuals diagnosed with CCA and possessing FGFR2 gene fusion who had previously undergone at least 1 round of chemotherapy treatment.

The median PFS was 5.4 months (95% CI, 3.7-5.6), and the median OS was 13.1 months (95% CI, 10.8-17.4). A total of 61 (96.8%) patients had ≥1 treatment-related adverse events (TRAEs); the most common was hyperphosphatemia (51 patients; 81.0%).

The most common grade 3 TRAEs included increased lipase (4 patients; 6.3%), hyperphosphatemia (3 patients; 4.8%), and palmar-plantar erythrodysesthesia syndrome (2 patients; 3.2%).

Thirty-four (53.9%) patients had a dose reduction, and 18 (28.6%) had a treatment interruption due to a treatment-emergent adverse event.7

Tasurgratinib demonstrated encouraging efficacy in individuals diagnosed with CCA and possessing FGFR2 gene fusion who had previously undergone at least 1 round of chemotherapy treatment.

Tasurgratinib demonstrated an overall manageable safety profile, which remained consistent with prior studies and the expected pharmacologic behavior of FGFR inhibitors.4,8-10


  1. Ronnekleiv-Kelly SM, Pawlik TM. Staging of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6(1):35-43.
  2. Patel T. Cholangiocarcinoma—controversies and challenges. Nat Rev Gastroenterol Hepatol. 2011;8(4):189-200.
  3. National Institutes of Health. National Cancer Institute. Bile duct Cancer (cholangiocarcinoma) treatment (PDQ)–health professional version. Updated December 12, 2023. Accessed February 27, 2024. www.cancer.gov/types/liver/hp/bile-duct-treatment-pdq
  4. Maruki Y, Morizane C, Arai Y, et al. Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE study) [published correction appears in J Gastroenterol. December 30, 2020]. J Gastroenterol. 2021;56(3):250-260.
  5. Watanabe SM, Yamamoto Y, Kodama K, et al. E7090, a novel selective inhibitor of fibroblast growth factor receptors, displays potent antitumor activity and prolongs survival in preclinical models. Mol Cancer Ther. 2016;15(11):2630-2639.
  6. Koyama T, Shimizu T, Iwasa S, et al. First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. Cancer Sci. 2020;111(2):571-579.
  7. Furuse J, Jiang B, Kuwahara T, et al. Pivotal single-arm, phase 2 trial of tasurgratinib for patients with fibroblast growth factor receptor (FGFR)-2 gene fusion-positive cholangiocarcinoma (CCA). San Francisco, CA, & online: presented at ASCO Gastrointestinal Cancers Symposium; January 18-20, 2024: poster B16.
  8. Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study [published correction appears in Lancet Oncol. 2024 Jan;25(1):e3]. Lancet Oncol. 2020;21(5):671-684.
  9. Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388(3):228-239.
  10. Javle MM, Roychowdhury S, Kelley RK, et al. Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement. J Clin Oncol. 2021;39(suppl 3):265-265.

Related Items

Safety and Efficacy of Telotristat Ethyl Plus First-Line Chemotherapy in Patients With Advanced BTC: A Phase 2, Open-Label Study
March 2024, Vol 5, No 1
Richard Kim, MD, presented the results of a phase 2, open-label study of patients who underwent telotristat ethyl plus first-line chemotherapy for the treatment of advanced biliary tract cancer.
Efficacy and Safety of Brigimadlin (BI 907828) in Patients With Advanced BTC: Data From 2 Phase 1a/1b Dose-Escalation/Expansion Trials
March 2024, Vol 5, No 1
Teresa Macarulla, MD, PhD, presented the results of 2 phase 1a/1b dose-escalation/expansion trials, studies that measured the efficacy and safety of brigimadlin in patients with advanced biliary tract cancer.
COMPANION-002: A Phase 2/3 Randomized Study Design of CTX-009 Combination in Second-Line BTC
March 2024, Vol 5, No 1
A recombinant bispecific antibody, CTX-009, is discussed regarding its role in an ongoing phase 2/3 open-label, randomized, controlled study—a study being conducted to measure the efficacy of CTX-009 in previously treated, advanced, or metastatic biliary tract cancer.
A Phase 2 Clinical Trial of Anlotinib Plus TQB2450 (PD-L1 Blockade) Plus Nab-Paclitaxel and Cisplatin as First-Line Treatment for Advanced BTC
March 2024, Vol 5, No 1
Cholangiocarcinoma experts presented the preliminary results of a phase 2 clinical trial regarding anlotinib plus TQB2450, nab-paclitaxel, and cisplatin—a study conducted for the treatment of advanced biliary tract cancer.
Preliminary Results of a Real-World Study of the Safety and Efficacy of Surufatinib in BTC
March 2024, Vol 5, No 1
Zongli Zhang, MD, PhD, presented the preliminary results of an ongoing single-arm, multicenter, open-label, real-world study analyzing the efficacy and safety of surufatinib as a second-line treatment option for patients with biliary tract cancer.
Genomic Factors Indicating Sensitivity to IO and Chemotherapy in CCA
March 2024, Vol 5, No 1
Riya Jayesh Patel, MD, presented how the impact of transcriptomic signatures related to chemotherapy and immunotherapy sensitivity in the cholangiocarcinoma (CCA) cohort of The Cancer Genome Atlas could serve as evidence supporting the effectiveness of metabolism-targeted therapies in overcoming CCA therapeutic resistance.
Examining Real-World Testing, Treatment Patterns, and Outcomes After Liquid Biopsy in aCCA
March 2024, Vol 5, No 1
Amit Mahipal, MD, presented results from a real-world data study examining the rates of molecular alterations detected using circulating tumor DNA (ctDNA) for patients receiving ivosidenib following circulating tumor ctDNA-detected IDH1 mutations.
A Phase 2 Primary Analysis of Tislelizumab Plus Lenvatinib and GEMOX as Conversion Therapy in Potentially Resectable Locally Advanced BTC (ZSAB-TransGOLP)
March 2024, Vol 5, No 1
Jia Fan, PhD, presented results from a phase 2 trial that investigated the efficacy and safety of lenvatinib and a programmed cell death protein-1 antibody as conversion therapy for the treatment of potentially resectable and locally advanced biliary tract cancer.
Role of CD27 Agonist in Combination With PD-L1 and MEK Inhibition on Antitumor Effect and CD8+ T Cells: Expanding Immunotherapy Options in CCA
March 2024, Vol 5, No 1
Frances J. Bennett, MD, presented the results of a phase 2 trial that tested the antitumor effect of dual programmed death-ligand 1 plus mitogen-activated protein kinase inhibition in patients with advanced biliary tract cancer.
Phase 3 Study of Tinengotinib Versus Physician’s Choice in Patients With FGFR-Altered, Chemotherapy- and FGFR Inhibitor-R/R CCA: Study Design of FIRST-308
March 2024, Vol 5, No 1
FIRST-308 is an open-label, phase 2, randomized, global, multicenter study that will evaluate the efficacy and safety of oral tinengotinib versus physician’s choice in patients with fibroblast growth factor receptor (FGFR)-altered, chemotherapy- and FGFR inhibitor-refractory/relapsed cholangiocarcinoma—this article will review the study’s eligibility criteria, primary endpoints, and more.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: